Univeristy Medical Center Groningen
Groningen, Netherlands
Location status: Recruiting
Location contact
Else ter Haar, MD
CONTACT
Jorine Hartman, PhD
CONTACT
NCT Number: NCT06025500
Rationale: Chronic obstructive pulmonary disease (COPD) is characterised by a high prevalence of peripheral muscle dysfunction, which can have significant clinical consequences, including decreased exercise capacity, reduced quality of life, and even a higher mortality rate. Reduction of lung hyperinflation using bronchoscopic lung volume reduction treatment with one-way endobronchial valves (EBV) is a minimally invasive intervention which improves exercise capacity and physical activity in patients with severe emphysema. This positive effect is also related to weight gain and alterations in body composition. The physiologic and structural adaptations of skeletal muscle function after EBV treatment has never been investigated before.
Objective: To investigate the physiological and structural adaptations of peripheral muscle function at a cellular level in response to EBV treatment.
Study design: A single center, prospective clinical trial with a single-arm pretest-posttest design. Patients with severe emphysema who will receive a bronchoscopic lung volume reduction treatment are asked to undergo additional in-magnet exercise testing and muscle biopsies before and after placement of EBVs.
Study population: Patients with severe emphysema who are scheduled to undergo EBV treatment.
Main study parameters/endpoints: The difference in quadriceps phosphocreatine concentration (PCr), quadriceps inorganic phosphorus concentration (Pi), and quadriceps pH at rest, during progressive exercise, and recovery rate will be measured by 31P-MRS to assess the physiological effect of EBV treatment on skeletal muscle function and its bioenergetics. Furthermore, we will perform a detailed histological and biochemical analysis of muscle fiber type composition, mitochondrial density, master regulators of muscle oxidative programming, and mitochondrial respiration before and after EBV treatment.
Interested in participating?
Request InfoAll sexes
Observational
Groningen, Netherlands
Location status: Recruiting
Else ter Haar, MD
CONTACT
Jorine Hartman, PhD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.
Other names: Muscle biopsy
Time frame: 6 months
To assess the physiological adaptations, in terms of cellular bioenergetics, of the quadriceps muscle in patients with severe COPD in response to EBV treatment. This will be done by performing 31P-MRS during exercise testing in a MR-compatible ergometer at baseline and at 6 months follow-up, for which the quadriceps phosphocreatine concentration (PCr) at rest and during progressive exercise will be assessed.
Time frame: 6 months
Change in muscle fiber type composition 6 months after EBV treatment measured in muscle biopsies.
Contact information is provided by the study sponsor or research team.
Else ter Haar, MD
CONTACT
Jorine Hartman, PhD
CONTACT
University Medical Center Groningen
Other
Analysing cEllular Bioenergetics aNd Structural aDaptations in the qUadriceps Muscle befoRe and After endobroNChial Valve treatmEnt
Acronym: ENDURANCE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07715617
Alpha-1-antitrypsin Deficiency, Artificial Intelligence (AI)
Bron, France
View Trial DetailsNCT07097896
Chronic Disease, Disease Attributes
Beijing, Beijing Municipality, China
View Trial DetailsNCT07119229
COPD, Chronic Disease
San Francisco, California, United States
View Trial DetailsNCT07086339
COPD, Chronic Disease
Limoges, France
View Trial Details